title: Does thalidomide have an analgesic effect? Current status and future directions.
abstract: Dramatic relief of pain and life-altering changes in quality of life in some patients treated with immunomodulators such as thalidomide compel us to look more closely at unconventional mechanisms that may be involved in propagation of persistent pain. Tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, and IL-10 are the cytokines with the most evidence in pain modulation. TNF-alpha and IL-1beta seem to initiate neuropathic pain, IL-6 maintains such pain, and IL-10 inhibits this persistent pain. Thalidomide was found to be effective in animal models by inhibiting TNF-alpha production. Several case reports and case series in humans have demonstrated mixed results, with some patients having dramatic responses, especially in chronic intractable conditions such as complex regional pain syndrome. Thalidomide may be an alternative for some patients with intractable pain. However, use of thalidomide is limited by its neurotoxic and teratogenic effects. Newer analogues may significantly improve the risk/benefit of using such immunomodulators.
authors: Duke University Medical Center, 932 Morreene Road, Durham, NC 27705, USA. goli0001@mc.duke.edu
authors: Veeraindar
authors: V
authors: Goli
mesh_terms: D000818:Animals; D006801:Humans; D015213:Neuroimmunomodulation / Q000187:drug effects / Q000502:physiology; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D013792:Thalidomide / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D013792:Thalidomide